Climb Bio Extends Cash Runway to 2H 2028, Reports Q2 2026 Results, and Sets Key Clinical Milestones
CLYM has more than doubled off its 52-week low of $1.54.
Summary
Climb Bio reported Q2 2026 financials with a $239.2 million cash balance extending runway into 2H 2028, and outlined upcoming catalysts including CLYM116 Phase 1 data on September 3 and multiple budoprutug readouts in Q4 2026.
Key Events · Earnings and Guidance · CLYM
-
Q2 2026 Financial Results
Net loss of $13.5 million on $15.4 million in operating expenses; cash, equivalents, and marketable securities totaled $239.2 million as of June 30, 2026.
-
Cash Runway Extended to 2H 2028
Management expects the current cash balance to fund operations into the second half of 2028, supported by the $110 million private placement completed in April 2026.
-
CLYM116 Phase 1 Data at R&D Spotlight
Initial Phase 1 PK/PD data for CLYM116 in healthy volunteers will be presented at a company-hosted R&D Spotlight Event on September 3, 2026.
-
CLYM116 Phase 2 in IgAN to Start Q3 2026
Dosing in the Phase 2 portion of the Mabworks-led Phase 1/2 trial in IgA nephropathy patients is expected to begin in the third quarter of 2026.
Analysis · CLYM · Life Sciences
With a net loss of $13.5 million on $15.4 million in operating expenses, Climb Bio's Q2 2026 earnings highlight a robust cash position of $239.2 million that funds operations into the second half of 2028. The update also details a rich pipeline of catalysts: a September 3 R&D Spotlight for CLYM116 Phase 1 data, a planned Phase 2 initiation in IgA nephropathy this quarter, and multiple budoprutug data readouts in Q4 2026. Together, the extended runway and upcoming data releases reduce near-term financing risk and set the stage for a data-rich second half of the year.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 29.2% of the 1466 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLYM was trading at $12.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $714.1M. The 52-week trading range was $1.54 to $14.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.